Full TitleSingle Arm Phase II Study of Avutometinib (VS-6766) and Defactinib in Advanced or Recurrent Mesonephric Gynecologic Cancer
Mesonephric cancer is a rare gynecologic cancer. The purpose of this study is to assess the safety and effectiveness of giving VS-6766 and defactinib together in people with advanced or recurrent mesonephric gynecologic cancers.
VS-6766 and defactinib inhibit enzymes called kinases found on the surface of cancer cells, and cancer cells need these enzymes to survive and grow. When these enzymes are blocked, a cancer may stop growing or grow more slowly, and the cancer cells may shrink. VS-6766 and defactinib are both taken orally (by mouth).
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have mesonephric gynecologic cancer that has metastasized or came back after prior therapy.
- At least 4 weeks must pass since the completion of previous anti-cancer treatments and receipt of the study therapy.
- This study is for women age 18 and older.
For more information and to ask about eligibility for this study, please contact the office of Dr. Rachel Grisham at 646-888-4653.